Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tilrekimig
tilrekimig and rHuPH20 · 5 trials · 3 indications
Protocol defined asthma exacerbations require treatment with systemic steroids (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.
Number and percentage of participants with treatment-emergent adverse events. An adverse event is considered treatment-emergent if it begins or increases in severity following initiation of study intervention. Events will be summarized by severity and other protocol-defined characteristics
Number and percentage of participants with treatment-emergent serious adverse events. Serious adverse events are events that meet one or more of the protocol-defined seriousness criteria.
Number and percentage of participants with treatment-emergent adverse events that lead to permanent discontinuation of tilrekimig.
Number and percentage of participants with protocol-defined clinical abnormalities in laboratory values and vitals signs. Laboratory assessments include protocol-required hematology and blood chemistry evaluations. Abnormal laboratory findings will be evaluated according to protocol-defined criteria and investigator assessment of clinical significance. Vital-sign assessments include blood pressure, pulse rate, respiratory rate, temperature, and oxygen saturation measured by pulse oximetry.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm A Tilrekimig | EXPERIMENTAL | Tilrekimig |
| Treatment Arm B Placebo | PLACEBO_COMPARATOR | Placebo |
| Tilrekimig (PF-07275315) | EXPERIMENTAL | Tilrekimig (PF-07275315) subcutaneous injection (sc) |
| Tilrekimig - Initial treatment period | EXPERIMENTAL | Subcutaneous injections given over 20 Weeks. |
| Placebo - Initial treatment period | PLACEBO_COMPARATOR | Subcutaneous injections given over 22 Weeks. |
| Tilrekimig - Maintenance Period - Dose B | EXPERIMENTAL | Subcutaneous injections given at Week 24 through Week 48. |
| Tilrekimig - Maintenance Period - Dose A | EXPERIMENTAL | Subcutaneous injections given at Week 24 through Week 48. |
| Dupilumab - Initial treatment period | ACTIVE_COMPARATOR | Subcutaneous injections given over 22 Weeks. |
| Placebo - Maintenance Period | PLACEBO_COMPARATOR | Subcutaneous injections given at Week 24 through Week 48. |
| Tilrekimig | EXPERIMENTAL | Subcutaneous injections given over 20 weeks |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous injections given over 20 weeks |
| Name | Type | Description |
|---|---|---|
| tilrekimig | DRUG | subcutaneous injection |
| Placebo | OTHER | subcutaneous injection |
| Dupilumab | DRUG | Subcutaneous Injections at required timepoints based on weight and age. |
| Placebo for Tilrekimig | OTHER | Subcutaneous Injections at required timepoints |
| Placebo for Dupilumab | OTHER | Subcutaneous Injections at required timepoints during initial treatment period. |
Inclusion Criteria Must meet the following asthma criteria: 1. History of persistent, severe asthma for at least 12 months prior to screening as defined by recognized international and / or local guidelines. 2. Must have experienced at least 2 asthma exacerbations requiring treatment with systemic...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Tilrekimig is an investigational medicine being developed by Pfizer for respiratory and inflammatory conditions. It is in Phase 3 clinical development for severe asthma, atopic dermatitis, and moderate to severe chronic obstructive pulmonary disease. Tilrekimig has not been approved by the FDA and remains under clinical study.
Tilrekimig is being studied for severe asthma, atopic dermatitis, and moderate to severe chronic obstructive pulmonary disease. These are the indications under investigation in Phase 3 trials. Tilrekimig is investigational and has not been approved for any use.
Tilrekimig is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is running the Phase 3 clinical program evaluating Tilrekimig across asthma, atopic dermatitis, and chronic obstructive pulmonary disease.
Tilrekimig is in Phase 3 clinical development. Pfizer is running four Phase 3 trials across severe asthma, atopic dermatitis, and moderate to severe chronic obstructive pulmonary disease. Tilrekimig is investigational and has not received FDA approval.
Tilrekimig is being evaluated in four Phase 3 trials. NCT07869043 and NCT07772921 study severe asthma, NCT07783425 studies atopic dermatitis, and NCT07839884 is a continuation study in moderate to severe chronic obstructive pulmonary disease. All are randomized, double-blind, and placebo-controlled.